NCoA-3 Antibody (4i301): sc-71654
- NCoA-3 Antibody (4i301) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 605-1294 of NCoA-3 of human origin
- recommended for detection of NCoA-3 of human origin by WB, IP, IF and IHC(P)
- m-IgG1 BP-HRP is the preferred secondary detection reagent for NCoA-3 Antibody (4i301) for WB and IHC(P) applications. This reagent is now offered in a bundle with NCoA-3 Antibody (4i301) (see ordering information below).
NCoA-3 Antibody (4i301) is a mouse monoclonal IgG1 antibody that detects NCoA-3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. NCoA-3, also known as RAC3, ACTR, AIB-1, and p/CIP, plays a crucial role as a transcriptional coactivator in the steroid receptor family, facilitating the transcriptional activation of hormone-responsive genes. NCoA-3 (4i301) antibody enables research into protein functions involving the regulation of gene expression in response to steroid hormones, thyroid hormones, and retinoic acids, which are vital for numerous physiological processes, including development, metabolism, and homeostasis. Notably, NCoA-3 is often overexpressed in estrogen receptor-positive ovarian and breast cancers, highlighting its importance in cancer biology and potential as a therapeutic target. The interaction of NCoA-3 with other proteins, such as p300/CBP, underscores its role in enhancing transcriptional activity, making anti-NCoA-3 antibody (4i301) a key tool for investigating the mechanisms of hormone signaling and cancer progression.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
NCoA-3 Antibody (4i301) References:
- NCOA3 Loss Disrupts Molecular Signature of Chondrocytes and Promotes Posttraumatic Osteoarthritis Progression. | Zhang, B., et al. 2018. Cell Physiol Biochem. 49: 2396-2413. PMID: 30261507
- The Rac3 GTPase in Neuronal Development, Neurodevelopmental Disorders, and Cancer. | de Curtis, I. 2019. Cells. 8: PMID: 31514269
- Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma Susceptibility. | de Semir, D., et al. 2021. Cancer Res. 81: 2956-2969. PMID: 33766890
- NCOA3 is a critical oncogene in thyroid cancer via the modulation of major signaling pathways. | Li, Y., et al. 2022. Endocrine. 75: 149-158. PMID: 34251576
- NCOA3, a new player in melanoma susceptibility and a therapeutic target. | Bezrookove, V. and Kashani-Sabet, M. 2022. Cancer Gene Ther. 29: 399-401. PMID: 35322161
- Variant-specific changes in RAC3 function disrupt corticogenesis in neurodevelopmental phenotypes. | Scala, M., et al. 2022. Brain. 145: 3308-3327. PMID: 35851598
- NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile. | Lira, MC., et al. 2023. Oncol Rep. 49: PMID: 37026525
- AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer. | Kiliti, AJ., et al. 2023. Front Endocrinol (Lausanne). 14: 1250218. PMID: 37711895
- GTF2H4 regulates partial EndMT via NF-κB activation through NCOA3 phosphorylation in ischemic diseases. | Fang, Z., et al. 2024. Innovation (Camb). 5: 100565. PMID: 38379791
- Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant bladder cancer cells. | Li, H., et al. 2024. J Cell Mol Med. 28: e18473. PMID: 38847477
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NCoA-3 Antibody (4i301) | sc-71654 | 200 µg/ml | $322.00 | |||
NCoA-3 Antibody (4i301): m-IgG1 BP-HRP Bundle | sc-542617 | 200 µg Ab; 20 µg BP | $361.00 |